Background: The elderly are at a higher risk of morbidity and mortality associated with
influenza infection than younger adults, but get less protection from conventional …

Background In the elderly, traditional influenza inactivated vaccines are often only modestly
immunogenic, owing to immunosenescence. Given that adjuvantation is a means of …

Aim Adjuvanted influenza vaccines can overcome the poor antibody response of
conventional non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity …

Background A number of enhanced influenza vaccines have been developed for use in
older adults, including high-dose, MF59-adjuvanted, and intradermal vaccines. Methods We …

Elderly people are at great risk for influenza‐related serious complications. However,
influenza vaccine‐induced antibodies are believed to decline more rapidly in the elderly …

Safety and immunogenicity of the influenza vaccine adjuvanted with MF59 (FLUADTM) were
compared to those of a non adjuvanted subunit vaccine in elderly subjects during three …

The influenza vaccination is known as the most effective method for preventing influenza
infection and its complications in the elderly. Conventional subunit (Agrippal S1; Novartis) …

Objectives MF59-adjuvanted standard-dose and nonadjuvanted high-dose seasonal
influenza vaccines have been developed to protect the elderly at high risk of severe …

Background: MF59-adjuvanted influenza vaccines have superior immunogenicity in older
adults compared with non-adjuvanted vaccines. We assessed whether changing formulation …

The adjuvanted influenza vaccine FLUAD™ is composed of subunit influenza antigens
combined with the MF59-adjuvant emulsion. The vaccine was developed primarily for use in …